Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Opportunities missed to review mefloquine use in the UK military

The antimalarial drug mefloquine (Lariam) is notorious for inducing neuropsychiatric effects in some users[1]. From 1993 onwards it was dispensed routinely to around 2,000 UK military personnel each year, mostly soldiers training in the Nanyuki Highlands of central Kenya (and where, ironically, there is almost no malaria).

ThePharmaceutical Journal has performed a valuable service in highlighting the difficulties facing armed forces personnel who were damaged by mefloquine, and who are now seeking compensation[2],[3]. As of this month, there are over 1,000 serving and retired military personnel in this category.

On 13 September 2016, BBC Radio Four’s Today programme featured an interview between presenter John Humphrys and a representative from the Ministry of Defence (MoD)[4]. Humphrys asked the hapless ministry spokesperson if he accepted that its mefloquine dispensing demonstrated “long-term malpractice for more than 20 years”.

The MoD man dodged the question and asserted that in the past ten years the “vast majority” of its antimalarial prescriptions were accomplished “entirely correctly”[4].

The lawyers are likely to take a different view and argue that there was a specific date in time — in legal parlance, the date of knowledge — when the MoD should have known that mefloquine was uniquely dangerous in deployed troops, after which mefloquine should have been prescribed only with the utmost caution, if at all. When was this date of knowledge? I offer three possibilities:

On 1 October 2001, the first ever randomised controlled trial of mefloquine in tourist and general travellers was published[5]. It showed a clear excess of neuropsychiatric events in mefloquine users. Hastily, some national armies, e.g. Denmark and The Netherlands, stopped prescribing mefloquine to their troops.

On 1 October 1996, the Committee on Safety of Medicines (CSM — the Medicines and Healthcare products Regulatory Agency’s forerunner) advised UK doctors to warn patients who were being prescribed mefloquine about the drug’s neuropsychiatric side effects[6]. Plainly, the MoD did not do this.

On or around 20 December 1995, a UK soldier who was taking mefloquine during an Army-run clinical trial in Kenya killed himself. This came at an acutely embarrassing time for the MoD, since the previous month the BBC television programme Watchdog had highlighted the neuropsychiatric dangers of Lariam[7]. As the Defence Committee was recently informed[8],[9], the MoD seemingly panicked, and concealed from the responsible authorities (Coroner, the CSM) this fatal outcome in a controlled clinical study. Doubtless, it hoped the problem would go away. It didn’t.

Ashley Croft

Consultant public health physician – defence committee witness

Served in the Royal Army Medical Corps from 1986–2013

University of Portsmouth

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20201729

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Patient Care in Community Practice

    Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00Buy now
  • Pharmacy OSCEs

    Pharmacy OSCEs

    The only pharmacy-specific OSCE revision guide. This easy-to-use book covers the key competencies that will be tested in your exams.

    £25.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • Physicochemical Principles of Pharmacy

    Physicochemical Principles of Pharmacy

    This established textbook covers every aspect of drug properties from the design of dosage forms to their delivery by all routes to sites of action in the body.

    £48.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.